TNFSF10 and plasma cell myeloma: Importantly, it has been shown that myeloma cells can develop resistance to TRAIL [34]–[35]; however, conventional chemotherapeutic drugs can sensitise these resistant cells to TRAIL through up-regulation and activation of death receptors R1 and R2 [35]–[36].